Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Apr
02
Today In Oncology
Financial Hardship and Late-Stage Cancer Diagnosis
Agent Orange Exposure Linked to MDS Risk and Progression
One-Time Low-Dose CT Screening May Reduce Lung Cancer Mortality Among Neversmokers in Asia
Low-Risk Endometrial Cancer Does a Lack of Adjuvant Therapy Affect Survival
ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo